Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.37 |
| ▸ | DRD1 | P21728 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 8/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 3/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612962 | 0.87 | HTR1A (0.39) | DRD2DRD1HTR1AHTR7PPARG | |
| SCHEMBL3613409 | 0.84 | DRD2 (0.30) | DRD2DRD1 | |
| SCHEMBL3609202 | 0.81 | PPARD (0.42) | DRD2DRD1HTR2APPARGPPARD | |
| SCHEMBL3614238 | 0.78 | ROCK2 (0.37) | — | |
| SCHEMBL3609022 | 0.76 | PPARD (0.43) | DRD2DRD1PPARGPPARDPPARA | |
| SCHEMBL3613299 | 0.73 | RORC (0.33) | — | |
| SCHEMBL3610528 | 0.73 | GHSR (0.30) | PPARGPPARDPPARA | |
| Hydrochloric Acid SCHEMBL3613472 | 0.73 | RORC (0.33) | — | |
| Hydrochloric Acid SCHEMBL3602849 | 0.73 | RORC (0.36) | — | |
| SCHEMBL3612843 | 0.72 | GHSR (0.35) | PPARGPPARDPPARALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737148-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7157462-B2 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2007-01-02 | — | — | US | disclosed |
| US-20050059671-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059671-A1 | Therapeutic agents useful for treating pain | OPRL1, OPRK1, ARRB1 | DRD2 96/4885DRD1 171/4885HTR1A 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.